Form 4: Bolt Biotherapeutics Director Jakob Dupont Receives Stock Option Grant

Bolt Biotherapeutics, Inc. Director Jakob Dupont was granted 1,100 stock options at an exercise price of $6.40, reflecting a post-reverse stock split adjustment.

Summary

• Director Jakob Dupont of Bolt Biotherapeutics, Inc. was granted 1,100 stock options (right to buy) for the company's common stock on May 27, 2025.
• The exercise price for these options is $6.40 per share.
• The options are set to vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, contingent on continuous service.
• Full vesting of the options will occur upon a change in control of Bolt Biotherapeutics, Inc.
• The options have an expiration date of May 26, 2035.
• On June 6, 2025, Bolt Biotherapeutics effected a 1-for-20 reverse stock split of its common stock; all reported share and exercise price amounts reflect this adjustment.
• Prior to the reverse stock split, the grant was for 22,000 shares at an exercise price of $0.3200 per share.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholder value creation, incentivizing long-term performance. However, it is a routine compensation disclosure rather than a direct indicator of immediate financial performance or operational success.

Positives

• The grant of stock options to Director Jakob Dupont aligns his financial interests with those of the shareholders, incentivizing long-term company performance and value creation.

Negatives

• The stock options are subject to a vesting schedule, requiring Director Dupont to maintain continuous service to fully realize the benefit of the grant.
• The value of the options is contingent on the future market price of Bolt Biotherapeutics common stock exceeding the exercise price, introducing market risk.

Risks

• The value of the stock options is directly dependent on the future market price of Bolt Biotherapeutics common stock remaining above the exercise price of $6.40 per share.
• Vesting of the options is contingent on Director Dupont's continuous service through the specified vesting dates, and the options could be forfeited if service terminates prematurely.
• The 1-for-20 reverse stock split, while reflected in the option terms, can sometimes be perceived negatively by the market, though this filing only reports the adjusted terms.

Future Outlook

The stock options granted to Director Jakob Dupont are scheduled to vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, contingent on his continuous service. This indicates a future increase in his beneficial ownership of Bolt Biotherapeutics common stock if these conditions are met, with full vesting accelerated upon a change in control of the Issuer.

Industry Context

This Form 4 filing represents a routine disclosure of an insider equity grant, which is a common practice in the biotechnology sector. Such grants are typically used to compensate and incentivize key personnel, including directors, by aligning their financial interests with the long-term performance and strategic goals of the company within the highly capital-intensive and research-driven biotech industry.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across various industries, including biotechnology, serving to align the interests of the board with those of shareholders.
• The specific terms of the option grant, such as the exercise price and vesting schedule, are generally evaluated against compensation benchmarks for directors at peer companies of similar size, stage of development, and market capitalization within the biotech sector, although no specific comparative data is provided in this filing.

Related Party Transactions

• The grant of stock options to Director Jakob Dupont constitutes a related party transaction, as it involves compensation provided by Bolt Biotherapeutics, Inc. to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aims to align Director Dupont's interests with shareholder value creation, potentially leading to more focused long-term strategic decisions. Future exercise of options could lead to minor dilution.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Director Jakob Dupont's continued service to Bolt Biotherapeutics, Inc. to fulfill the vesting conditions of the stock options.
• The occurrence of the next annual meeting of stockholders, which could trigger an earlier vesting of the options.
• Potential exercise of the stock options by Director Dupont upon vesting, assuming the market price of Bolt Biotherapeutics common stock is favorable.

Key Dates

Keywords

Bolt Biotherapeutics, BOLT, stock options, director compensation, SEC Form 4, insider transaction, equity grant, reverse stock split, vesting, corporate governance